A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers

Trial Profile

A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Nanobiotix
  • Most Recent Events

    • 09 Nov 2017 According to a Nanobiotix media release, results from this trial will be presented at ASCO GI conference in 2018.
    • 09 Nov 2017 According to a Nanobiotix media release, first set of trial data are expected in January 2018.
    • 04 Apr 2017 Nanobiotix aims to complete patient recruitment for the Phase I part of this trial, and may proceed to select the patient population for the dose-expansion part of the trial (Phase II) before the end of 2017, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top